On Tuesday, Cytokinetics Inc (NASDAQ: CYTK) opened lower -2.53% from the last session, before settling in for the closing price of $49.02. Price fluctuations for CYTK have ranged from $32.70 to $110.25 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 12.30% over the past five years. Company’s average yearly earnings per share was noted 3.38% at the time writing. With a float of $113.56 million, this company’s outstanding shares have now reached $117.89 million.
Let’s look at the performance matrix of the company that is accounted for 423 employees. In terms of profitability, gross margin is -2872.48%, operating margin of -16297.79%, and the pretax margin is -17906.24%.
Cytokinetics Inc (CYTK) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cytokinetics Inc is 3.77%, while institutional ownership is 113.13%. The most recent insider transaction that took place on Dec 16 ’24, was worth 36,069. In this transaction Director of this company sold 742 shares at a rate of $48.61, taking the stock ownership to the 24,559 shares. Before that another transaction happened on Dec 16 ’24, when Company’s Director proposed sale 742 for $48.61, making the entire transaction worth $36,069.
Cytokinetics Inc (CYTK) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to -22.79% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Check out the current performance indicators for Cytokinetics Inc (CYTK). In the past quarter, the stock posted a quick ratio of 9.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1751.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.39, a number that is poised to hit -1.24 in the next quarter and is forecasted to reach -5.37 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Cytokinetics Inc (NASDAQ: CYTK) saw its 5-day average volume 1.07 million, a negative change from its year-to-date volume of 1.99 million. As of the previous 9 days, the stock’s Stochastic %D was 14.96%. Additionally, its Average True Range was 1.71.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 2.88%, which indicates a significant decrease from 7.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 22.53% in the past 14 days, which was lower than the 38.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $52.42, while its 200-day Moving Average is $57.33. Nevertheless, the first resistance level for the watch stands at $48.75 in the near term. At $49.73, the stock is likely to face the second major resistance level. The third major resistance level sits at $50.41. If the price goes on to break the first support level at $47.09, it is likely to go to the next support level at $46.41. The third support level lies at $45.43 if the price breaches the second support level.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
There are currently 118,014K shares outstanding in the company with a market cap of 5.64 billion. Presently, the company’s annual sales total 7,530 K according to its annual income of -526,240 K. Last quarter, the company’s sales amounted to 460 K and its income totaled -160,550 K.
